Secoverine is a selective muscarinic receptor antagonist that was studied as a neurotropic spasmolytic agent. It was shown that the drug had no nicotinolytic or antihistaminic activity, a moderate antisterotonic activity, an inhibiting effect on the noradrenaline uptake mechanism of the vas deferens and marked local anesthetic activity.

Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of the non-steroidal anti-inflammatory drug (NSAID) naproxen that is hydrolysed to pharmacologically active naproxen once absorbed. Naproxen etemesil was in development with Logical Therapeutics for the treatment of osteoarthritis. However, no recent development has been reported. It is also in phase I clinical trials for the treatment of inflammation and arthritis.The compound was originally developed by Medinox, licensed to Logical Therapeutics in 2006 for partial rights.

Phetharbital (Pyrictal), a barbiturate with virtually no hypnotic side effects, was originally introduced for the management of epilepsy and has since been shown to have powerful hepatic enzyme-inducing properties. In preliminary clinical studies, phetharbital was found to be effective against febrile seizures, minor myoclonic seizures and in petit mal. Phetharbital is relatively ineffective in the control of the tonic extensor seizure pattern and would not be expected to modify grand mal tonic seizures. Chronic administration of phetharbital causes an increased excretion of 6 beta-hydroxycortisol in human urine. This increase in 6 beta-hydroxycortisol excretion is not accompanied by an increase in the 17-hydroxycorticosteroids levels in urine, indicating that an increased adrenal output of cortisol is not responsible for the increased urinary levels of 6 beta hydroxycortisol. Phetharbital was also effective in the rare severe unconjugated hyperbilirubinemia of the Crigler-Najjar syndrome.

Oxydipentonium, a cholinesterase inhibitor was studied as a muscle relaxant. Information about the further development of this drug is not available.

Penoctonium, a chemotherapeutic agent was used in microbial studies. However, information about the further development of this compound is not available.

Nafenodone [LU 39821] is a potent and selective inhibitor of norepinephrine and serotonin uptake. Its development for the treatment of anxiety disorders, major depressive disorder and psychotic disorders has been discontinued.

Dinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demostrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.) that began in 1998. Dinaciclib showed promising effect in treating haematological malignancies and solid tumors.

Hydrargaphen (also known as penotrane) was studied in trials for patients with herpes genitalia. In the treatment of Trichomonas vaginalis infections, penotrane was the suitable treatment for those patients who have not responded to other treatments. Information about the current use of this drug is not available.

Guanoctine was studied as an antihypertensive agent.